Core Viewpoint - Senxuan Pharmaceutical reported a revenue increase of 5.90% year-on-year for the first three quarters of 2025, driven by improved product quality and service, successful commercialization of new raw materials, and enhanced operational efficiency [1][2] Group 1: Financial Performance - For the first three quarters of 2025, Senxuan Pharmaceutical achieved a revenue of 411 million yuan, a year-on-year increase of 5.90% [1] - The net profit attributable to shareholders for the same period was 104 million yuan, reflecting a year-on-year growth of 13.45% [1] - In the third quarter alone, the company reported a revenue of 150 million yuan, marking a significant year-on-year increase of 29.45% [1] - The net profit for the third quarter was 35.736 million yuan, which is a remarkable year-on-year growth of 64.79% [1] Group 2: Growth Drivers - The revenue growth was attributed to three main factors: improved product quality and service leading to increased market share, successful commercialization of new raw materials, and ongoing internal management optimization [1] - The company plans to ensure long-term stable growth by advancing the overseas registration of both new and existing products, particularly in high-end regulatory markets in Europe and the United States [1] Group 3: R&D and Market Expansion - Research and development expenses decreased by 12.73% year-on-year, primarily due to some projects reaching maturity and reduced investment in early-stage projects [2] - Despite the decrease, the company emphasized that its commitment to R&D remains strong, focusing on high-potential therapeutic areas such as antiviral, anti-tumor, and anti-epileptic treatments [2] - The subsidiary, Luhua Senxuan, has successfully entered markets in engineering plastics, fibers, and pharmaceuticals, with plans to expand into new applications and markets, including Russia and Southeast Asia [2] - An industry standard for 1,3-Dioxolane, led by Luhua Senxuan, is set to be implemented in March 2026, which is expected to enhance the brand influence in the new materials sector [2]

Investment Rating - The investment rating for the company is upgraded to "Outperform" [2] Core Views - The company reported a revenue of 537 million yuan in 2024, a year-on-year decline of 8.89%, with a net profit attributable to the parent company of 124 million yuan, down 8.00% year-on-year [2] - The company has increased its patent count to 192, with 42 invention patents, indicating a strong focus on research and development [3] - The company is implementing a strategy to refine its raw material drug structure, specialize in intermediates, and expand into new materials and innovative drugs [4] Financial Summary - The company achieved a revenue of 590 million yuan in 2023, with a projected revenue of 706 million yuan by 2027, reflecting a compound annual growth rate [5] - The gross profit margin is expected to remain stable around 43.4% to 43.9% from 2025 to 2027 [5] - The earnings per share (EPS) is projected to increase from 0.30 yuan in 2025 to 0.41 yuan in 2027 [5] Revenue and Profit Forecast - The forecast for net profit attributable to the parent company is adjusted to 130 million yuan for 2025, 153 million yuan for 2026, and 174 million yuan for 2027 [2][5] - The company anticipates a slight revenue increase in 2025, with a projected revenue of 544 million yuan, followed by a more significant growth in subsequent years [5] Market Position and Product Development - The company has successfully registered new raw materials in the European and American markets, which is expected to contribute to future revenue growth [3] - The production of the new raw material drug projects is underway, with a focus on expanding the product line [3]